Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry.

Gisondi P, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, Girolomoni G, Naldi L; Psocare Study Group..

J Eur Acad Dermatol Venereol. 2013 Jan;27(1):e30-41. doi: 10.1111/j.1468-3083.2012.04450.x.

PMID:
22313340
2.

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry.

Piaserico S, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, Peserico A, Naldi L; Psocare Study Group..

J Am Acad Dermatol. 2014 Feb;70(2):257-62.e3. doi: 10.1016/j.jaad.2013.10.019.

PMID:
24355410
3.

The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.

Gottlieb AB, Kalb RE, Blauvelt A, Heffernan MP, Sofen HL, Ferris LK, Kerdel FA, Calabro S, Wang J, Kerkmann U, Chevrier M.

J Am Acad Dermatol. 2012 Oct;67(4):642-50. doi: 10.1016/j.jaad.2011.10.020.

PMID:
22153792
4.

Prolonged cyclosporine treatment of severe or recalcitrant psoriasis: descriptive study in a series of 20 patients.

Borghi A, Corazza M, Mantovani L, Bertoldi AM, Giari S, Virgili A.

Int J Dermatol. 2012 Dec;51(12):1512-6. doi: 10.1111/j.1365-4632.2012.05571.x.

PMID:
23171021
5.

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, Goyal K, Fakharzadeh S, Calabro S, Chevrier M, Langholff W, You Y, Leonardi CL.

JAMA Dermatol. 2015 Sep;151(9):961-9. doi: 10.1001/jamadermatol.2015.0718.

PMID:
25970800
6.

Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.

Carretero G, Ferrandiz C, Dauden E, Vanaclocha Sebastián F, Gómez-García FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina-Gibert M, López-Estebaranz JL, Ferrán M, Torrado R, Carrascosa JM, Carazo C, Rivera R, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group..

J Eur Acad Dermatol Venereol. 2015 Jan;29(1):156-63. doi: 10.1111/jdv.12492.

PMID:
24684267
7.

Long-term durability and dose escalation patterns in infliximab therapy for psoriasis.

Luber AJ, Tsui CL, Heinecke GM, Lebwohl MG, Levitt JO.

J Am Acad Dermatol. 2014 Mar;70(3):525-32. doi: 10.1016/j.jaad.2013.10.059.

PMID:
24388425
8.

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB.

J Am Acad Dermatol. 2007 Jan;56(1):31.e1-15.

PMID:
17097378
9.

Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project.

Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, Maccarone M, Chatenoud L, Bertuccio P, Caggese E, Cuscito R.

Dermatology. 2008;217(4):365-73. doi: 10.1159/000156599.

PMID:
18810241
10.

Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.

Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM.

Br J Dermatol. 2009 Mar;160(3):670-5. doi: 10.1111/j.1365-2133.2008.09019.x.

PMID:
19210502
11.

The treatment of psoriasis with etretinate and acitretin: a follow up of actual use.

Magis NL, Blummel JJ, Kerkhof PC, Gerritsen RM.

Eur J Dermatol. 2000 Oct-Nov;10(7):517-21.

12.

Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).

Barker J, Hoffmann M, Wozel G, Ortonne JP, Zheng H, van Hoogstraten H, Reich K.

Br J Dermatol. 2011 Nov;165(5):1109-17. doi: 10.1111/j.1365-2133.2011.10615.x.

PMID:
21910713
13.

Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine.

Opmeer BC, Heydendael VM, De Borgie CA, Spuls PI, Bossuyt PM, Bos JD, De Rie MA.

Arch Dermatol. 2004 Jun;140(6):685-90.

PMID:
15210458
14.

Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.

Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, Wain M, Barker JN.

Br J Dermatol. 2006 Jul;155(1):160-9.

PMID:
16792769
15.

Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy).

Sánchez-Regaña M, Sola-Ortigosa J, Alsina-Gibert M, Vidal-Fernández M, Umbert-Millet P.

J Eur Acad Dermatol Venereol. 2011 May;25(5):579-86. doi: 10.1111/j.1468-3083.2010.03938.x.

PMID:
21198950
16.

Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.

McIntyre RS, Jerrell JM.

Arch Pediatr Adolesc Med. 2008 Oct;162(10):929-35. doi: 10.1001/archpedi.162.10.929.

PMID:
18838645
17.

Efficacy and safety of systemic treatments for psoriasis in elderly patients.

Piaserico S, Conti A, Lo Console F, De Simone C, Prestinari F, Mazzotta A, Gualdi G, Guarneri C, Borsari S, Cassano N.

Acta Derm Venereol. 2014 May;94(3):293-7. doi: 10.2340/00015555-1719.

18.

Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.

Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

J Am Acad Dermatol. 2010 Dec;63(6):1011-8. doi: 10.1016/j.jaad.2009.12.029.

PMID:
20933301
19.

Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure.

Lowe NJ, Wieder JM, Rosenbach A, Johnson K, Kunkel R, Bainbridge C, Bourget T, Dimov I, Simpson K, Glass E, Grabie MT.

J Am Acad Dermatol. 1996 Nov;35(5 Pt 1):710-9.

PMID:
8912566
20.

The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study.

Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, Kremer E, Heymann A.

J Am Acad Dermatol. 2007 Apr;56(4):629-34.

PMID:
17157411
Items per page

Supplemental Content

Support Center